Skip to main content
AEON Biopharma, Inc. logo

AEON Biopharma, Inc. — Investor Relations & Filings

Ticker · AEON ISIN · US00775E1029 US Manufacturing
Open in API
Filings indexed 317 across all filing types
Latest filing 2023-07-25 Director's Dealing
Country US United States of America
Listing US AEON

About AEON Biopharma, Inc.

https://www.aeonbiopharma.com/

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused exclusively on developing therapeutic applications for botulinum toxins. The company is advancing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for the treatment of debilitating nervous system-related and neuromuscular disorders. Its lead clinical programs are investigating ABP-450 for the prevention of chronic and episodic migraines and the treatment of cervical dystonia. By concentrating solely on therapeutic indications, AEON aims to unlock the full potential of neurotoxins to provide lasting relief for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2023-07-25 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-07-25 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by AEON Biopharma, Inc. The key content is the disclosure of an Investor Presentation (Exhibit 99.1) dated July 2023. The text explicitly states that the presentation is attached as an exhibit and is being furnished pursuant to Regulation FD and Item 7.01 of Form 8-K. The document does not contain the full presentation text itself but references it as an attachment. The primary purpose is to announce and furnish the Investor Presentation to investors and the public. According to the classification rules, when a document is primarily an announcement or furnishing of an investor presentation, it should be classified as Investor Presentation (IP). The document length is 5507 characters, which is sufficient to contain substantive content, but the main body is a regulatory filing referencing the presentation. Therefore, the best fit is Investor Presentation (IP) with high confidence.
2023-07-24 English
NYSE AMERICAN CERTIFICATION
Regulatory Filings
2023-07-21 English
25
Delisting Announcement
2023-07-21 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It relates to the registration of the company's Class A common stock and warrants on the NYSE American, transferring listing from Nasdaq. The document is a registration statement, not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and listing, which fits best under the category of Regulatory Filings (RNS). The document length is 3793 characters, which is relatively short and consistent with a regulatory filing rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-07-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.